Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.
about
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.The Peripheral and Intratumoral Immune Cell Landscape in Cancer Patients: A Proxy for Tumor Biology and a Tool for Outcome Prediction.Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.Biomarkers for Immune Checkpoint Inhibitors in MelanomaNeoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
P2860
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@en
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@nl
type
label
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@en
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@nl
prefLabel
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@en
Phenotypic and functional test ...... d with neoadjuvant ipilimumab.
@nl
P2093
P2860
P1476
Phenotypic and functional test ...... ed with neoadjuvant ipilimumab
@en
P2093
Ahmad A Tarhini
Hui-Min Lin
Janet Retseck
Robert VanderWeele
P2860
P2888
P356
10.1186/S40425-016-0141-1
P577
2016-06-21T00:00:00Z
P6179
1020337279